StockData
Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc. (RYTM) stock

RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30265% above fair value
$115.02+5.16 (+4.70%)

Close on Nov 13, 2026Market cap $7.92BP/E –Yield –

Earnings

Rhythm Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$92.10M
+79.5% on a year earlier
EPS, Q3 FY2026
-$0.61
Latest guidance
Raised
Nov 3, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Rhythm Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026before the open$92.10M+79.5%-$0.61Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026before the open$71.30M+47.0%-$0.73Release
Q1 FY2026ended Mar 31, 2026May 5, 2026before the open$60.10M––Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$57.30M+37.1%-$0.73Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open$51.30M+54.1%–Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$48.50M+66.7%–Release
Q1 FY2025ended Mar 31, 2025May 7, 2025before the open––-$0.81Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025before the open$41.80M+72.7%-$0.72Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024after the close$33.30M+48.0%-$0.73Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open$29.10M+51.6%-$0.55Release
Q1 FY2024ended Mar 31, 2024May 7, 2024before the open$26.00M+126.1%-$2.35Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Rhythm Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Non-GAAP Operating Expensesnon-GAAPFY2026$360.00M – $380.00M$385.00M – $415.00MLoweredNov 3, 2026
Non-GAAP Operating Expensesnon-GAAPFY2026$363.00M – $397.00M$385.00M – $415.00MLoweredAug 4, 2026
R&D expensesGAAPFY2026$165.00M – $175.00M$188.00M – $202.00MLoweredNov 3, 2026
R&D expensesGAAPFY2026$175.00M – $195.00M$197.00M – $213.00MLoweredAug 4, 2026
SG&A expensesGAAPFY2026$195.00M – $205.00M$197.00M – $213.00MRaisedNov 3, 2026
SG&A expensesGAAPFY2026$188.00M – $202.00M$188.00M – $202.00MRaisedAug 4, 2026

Guidance history

Every forecast Rhythm Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026R&D expensesFY2026$165.00M – $175.00MLowered
Nov 3, 2026SG&A expensesFY2026$195.00M – $205.00MRaised
Nov 3, 2026Non-GAAP Operating ExpensesFY2026$360.00M – $380.00MLowered
Aug 4, 2026R&D expensesFY2026$175.00M – $195.00MLowered
Aug 4, 2026SG&A expensesFY2026$188.00M – $202.00MRaised
Aug 4, 2026Non-GAAP Operating ExpensesFY2026$363.00M – $397.00MLowered
May 5, 2026R&D expensesFY2026$197.00M – $213.00MNew
May 5, 2026SG&A expensesFY2026$188.00M – $202.00MLowered
May 5, 2026Non-GAAP Operating ExpensesFY2026$385.00M – $415.00MNew
Feb 26, 2026SG&A expensesFY2026$197.00M – $213.00MNew
Feb 26, 2026R&D expensesFY2026$188.00M – $202.00MLowered
Feb 26, 2026Non-GAAP Operating ExpensesFY2026$385.00M – $415.00MNew
Nov 4, 2025SG&A expensesFY2025$145.00M – $150.00MNew
Nov 4, 2025R&D expensesFY2025$150.00M – $165.00MRaised
Nov 4, 2025Non-GAAP Operating ExpensesFY2025$295.00M – $315.00MNew
Aug 5, 2025SG&A expensesFY2025$135.00M – $145.00MLowered
Aug 5, 2025R&D expensesFY2025$150.00M – $170.00MRaised
Aug 5, 2025Non-GAAP Operating ExpensesFY2025$285.00M – $315.00MReaffirmed
May 7, 2025SG&A expensesFY2025$135.00M – $145.00MLowered
May 7, 2025R&D expensesFY2025$150.00M – $170.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Rhythm Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
    Results
  2. © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® November 3, 2026 Rhythm Pharmaceuticals Third Quarter 2026 Financial Results and Business Update EXHIBIT 99.2
    Results
  3. Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
    Results
  4. Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
    Results
  5. © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® August 4, 2026 Rhythm Pharmaceuticals Second Quarter 2026 Financial Results and Business Update EXHIBIT 99.3
    Results
  6. Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
    Update
  7. 8-K exhibit EX-99.2
    Update
  8. Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
    Update
  9. Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
    Results
  10. Rhythm Pharmaceuticals Announces Changes to Board of Directors
    Update
  11. 8-K exhibit EX-99.1
    Update
  12. Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE ® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
    Update
  13. © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® March 19, 2026 Rhythm Pharmaceuticals IMCIVREE (Setmelanotide) FDA Approval in Acquired Hypothalamic Obesity EXHIBIT 99.2
    Update
  14. Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
    Update
  15. © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Phase 3 EMANATE Trial Topline Results March 16, 2026 EXHIBIT 99.2
    Update

See a number that looks wrong?